Prelude Capital Management’s Catalyst Pharmaceutical CPRX Stock Holding History

Prelude Capital Management’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-22,800	Closed	-$553K	–	1054
2025 Q1	$553K	Buy	+22,800	New	+$513K	0.04%	474
2024 Q4	–	Sell	-12,325	Closed	-$245K	–	1265
2024 Q3	$245K	Sell	12,325 -10,525	-46%	-$195K	0.01%	972
2024 Q2	$354K	Sell	22,850 -3,049	-12%	-$47.5K	0.02%	715
2024 Q1	$413K	Sell	25,899 -26,408	-50%	-$398K	0.02%	717
2023 Q4	$879K	Buy	52,307 +38,303	+274%	+$524K	0.06%	324
2023 Q3	$164K	Buy	+14,004	New	+$187K	0.01%	946
2019 Q3	–	Sell	-23,270	Closed	-$89K	–	1754
2019 Q2	$89K	Buy	+23,270	New	+$101K	﹤0.01%	977
2017 Q4	–	Sell	-270	Closed	-$1K	–	1407
2017 Q3	$1K	Sell	270 -540	-67%	-$1.48K	﹤0.01%	1567
2017 Q2	$2K	Buy	+810	New	+$1.69K	﹤0.01%	1522

Other funds holding CPRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Fundsmith LLP London, United Kingdom $12.8B AUM 6.9% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Prelude Capital Management's CPRX Position: Q2 2025 in Review

Prelude Capital Management sold out of Catalyst Pharmaceutical (CPRX) in Q2 2025, closing a stake of 22,800 shares — an estimated $553K sold.

Prelude Capital Management first reported a position in CPRX in Q2 2017 and held it in 9 quarters. The position peaked at $879K in Q4 2023. 365 funds tracked by Wall St. Rank hold CPRX as of Q2 2025.

Prelude Capital Management reported no remaining Catalyst Pharmaceutical position as of Q2 2025 after selling out during the quarter.
Prelude Capital Management sold 22,800 Catalyst Pharmaceutical shares in Q2 2025, an estimated $553K.
Prelude Capital Management first reported a position in Catalyst Pharmaceutical in Q2 2017 and held it in 9 quarters.
Prelude Capital Management's Catalyst Pharmaceutical position peaked at $879K in Q4 2023.
365 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2025.

Based on Prelude Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.